Abstract:
BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there is a lack of knowledge regarding a possible effect of NHT on PCRD in the high-risk PCa population. We aimed to analyze the effect of NHT on PCRD in a multicenter high-risk PCa population treated with RP, using a propensity-score adjustment. METHODS:This is a retrospective multi-institutional study including patients with high-risk PCa defined as: clinical stage T3-4, PSA >20 ng ml-1 or biopsy Gleason score 8-10. We compared PCRD between RP and NHT+RP using competing risks analysis. Correction for group differences was performed by propensity-score adjustment. RESULTS:After application of the inclusion/exclusion criteria, 1573 patients remained for analysis; 1170 patients received RP and 403 NHT+RP. Median follow-up was 56 months (interquartile range 29-88). Eighty-six patients died of PCa and 106 of other causes. NHT decreased the risk of PCRD (hazard ratio (HR) 0.5; 95% confidence interval (CI) 0.32-0.80; P=0.0014). An interaction effect between NHT and radiotherapy (RT) was observed (HR 0.3; 95% CI 0.21-0.43; P<0.0008). More specifically, of patients who received adjuvant RT, those who underwent NHT+RP had decreased PCRD rates (2.3% at 5 year) compared to RP (7.5% at 5 year). The retrospective design and lack of specific information about NHT are possible limitations. CONCLUSIONS:In this propensity-score adjusted analysis from a large high-risk PCa population, NHT before surgery significantly decreased PCRD. This effect appeared to be mainly driven by the early addition of RT post-surgery. The specific sequence of NHT+RP and adjuvant RT merits further study in the high-risk PCa population.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van ddoi
10.1038/pcan.2017.29subject
Has Abstractpub_date
2017-12-01 00:00:00pages
407-412issue
4eissn
1365-7852issn
1476-5608pii
pcan201729journal_volume
20pub_type
杂志文章abstract:BACKGROUND:Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT. METH...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-018-0084-3
更新日期:2019-03-01 00:00:00
abstract::We measured the histologic stromal and epithelial tissue components of the benign (normal) and malignant tissue compartments of Japanese-Americans (J-A) and native Japanese (NJ) men living in Japan. The patient cohort included 25 NJ men undergoing radical prostatectomy (RP) in Nagoya, Japan and 25 J-A (second or third...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500738
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2011.67
更新日期:2012-06-01 00:00:00
abstract:BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/pcan.2016.56
更新日期:2017-06-01 00:00:00
abstract::Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500940
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2014.28
更新日期:2014-12-01 00:00:00
abstract::This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre- and postoperative Gleason scores and a study dealing with tra...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500277
更新日期:1999-01-01 00:00:00
abstract::Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/sj.pcan.4500779
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,meta分析,评审
doi:10.1038/pcan.2016.51
更新日期:2017-03-01 00:00:00
abstract::Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bo...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500846
更新日期:2006-01-01 00:00:00
abstract::The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500517
更新日期:2001-01-01 00:00:00
abstract::We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group...
journal_title:Prostate cancer and prostatic diseases
pub_type: 临床试验,杂志文章
doi:10.1038/sj.pcan.4500675
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...
journal_title:Prostate cancer and prostatic diseases
pub_type: 临床试验,杂志文章
doi:10.1038/pcan.2015.55
更新日期:2016-03-01 00:00:00
abstract::In a prospective randomized study, we compare standard prostate biopsy to extensive biopsy utilizing intravenous conscious sedation (IVCS). Initial biopsy patients (n=197) were randomized to either standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1) or extensive biopsy (24 biopsies) using IVCS. ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1038/sj.pcan.4500713
更新日期:2004-01-01 00:00:00
abstract::The aim of the study was to evaluate factors of progression after radical prostatectomy in patients with bladder neck invasion (BNI). From 1988 to 2006, 1395 patients underwent radical prostatectomy, 120 (8.6%) had microscopic BNI (pT4 N0, TNM 2002). Group 1 was defined as BNI alone, group 2 as BNI plus extracapsular ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4501009
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-0202-x
更新日期:2020-09-01 00:00:00
abstract::Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/s41391-020-0258-7
更新日期:2020-09-01 00:00:00
abstract:INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500889
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2017.5
更新日期:2017-09-01 00:00:00
abstract::Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500483
更新日期:2000-12-01 00:00:00
abstract::Some patients with a histopathological diagnosis of prostate cancer have a tumour that behaves benignly during long-term follow-up. The proportion of patients with such a tumour is unknown, as is the fraction who die of prostate cancer between 10 and 20 y of follow-up. All men aged 45-84 y obtaining a diagnosis of pro...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500395
更新日期:2000-07-01 00:00:00
abstract::To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin ('Zoladex') or two leuprorelin ('Prostap') injections, using 16- or 23-gauge needles, respectively. Median visual analogue...
journal_title:Prostate cancer and prostatic diseases
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1038/sj.pcan.4500778
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:The Gleason grading system in prostatectomy specimens following receipt of neoadjuvant therapy has been considered inaccurate. However, with continuing expansion of novel therapeutics, it is important to understand whether the Gleason system can be effectively utilized in this setting. The aim of this study ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2014.30
更新日期:2014-12-01 00:00:00
abstract:BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1038/pcan.2011.49
更新日期:2012-03-01 00:00:00
abstract:BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2016.67
更新日期:2017-06-01 00:00:00
abstract::Prostate cancer has been known to run in families for about 40 years and epidemiological studies have demonstrated an increased risk to close relatives of cases. This risk rises markedly when the closeness and number of cases in a cluster increases. There has been considerable debate about the genetic model, in partic...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500279
更新日期:1999-01-01 00:00:00
abstract:BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2015.59
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,多中心研究
doi:10.1038/pcan.2014.13
更新日期:2014-09-01 00:00:00
abstract:BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2012.41
更新日期:2013-03-01 00:00:00
abstract::Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/sj.pcan.4500607
更新日期:2002-01-01 00:00:00